Figure 6
Trebananib and Dll4 antibodies have opposing effects on proliferation of TAECs in U-87-GFP human tumor xenografts. Mice with established U-87-GFP tumor xenografts were treated with a single injection of trebananib (5.6 mg/kg, s.c.), anti-Dll4 mouse monoclonal antibody (12 mg/kg, i.p.), or vehicle control (equivalent amount of human Fc or mouse IgG, respectively). Tumors were collected after 24 h (anti-Dll4 antibody group, n=6) and 48 h (trebananib group, n=6) along with corresponding time-matched vehicle-controls (n=6). Tumors were collected after treatment and processed for flow cytometry as outlined in Figures 1 and 4. (a) Trebananib or (b) anti-Dll4 antibody, dual parameter dot plots denoting BrdUrd-positive and negative region gates for individual tumor CD31high/CD45neg cell population and corresponding quantification of BrdUrd uptake. Plots represent BrdUrd uptake (percentage BrdUrd (+)) indicated as the mean between treatment groups. Statistically significant decrease or increase of BrdUrd uptake compared with vehicle-control group is denoted by an asterisk (trebananib, P=0.002; anti-Dll4 antibody, P=0.0007).
